Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Results from the LILAC study of ABP 980 with trastuzumab for HER2 early breast cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 1388

Dr Hans-Christian Kolberg - Marienhospital Bottrop, Bottrop, Germany

Dr Kolberg speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the phase III LILAC study, looking at ABP 980 with trastuzumab on pathologic complete response in women with HER2 early breast cancer.

He states that central evaluations support clinical equivalence of ABP 980 with trastuzumab and that the study demonstrates the feasibility of including central laboratory review of pathologic complete response rates in a large multi-centre, multinational study.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation